Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma
Condition(s):Urothelial CarcinomaLast Updated:November 4, 2021Active, not recruiting
Hide Studies Not Open or Pending
Condition(s):Urothelial CarcinomaLast Updated:November 4, 2021Active, not recruiting
Condition(s):Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral CancerLast Updated:November 2, 2012Terminated
Condition(s):Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter; Recurrent Bladder Cancer; Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter; Recurrent Urethral Cancer; Stage III Bladder Cancer; Stage III Urethral Cancer; Stage IV Bladder Cancer; Stage IV Urethral Cancer; Transitional Cell Carcinoma of the Bladder; Ureter CancerLast Updated:June 5, 2013Completed
Condition(s):Urothelial Carcinoma; Bladder Cancer; Renal Pelvis Cancer; Ureter Cancer; Urethra CancerLast Updated:April 26, 2019Completed
Condition(s):Upper Urinary Tract CarcinomaLast Updated:January 31, 2024Recruiting
Condition(s):Anterior Urethral Cancer; Localized Transitional Cell Cancer of the Renal Pelvis and Ureter; Posterior Urethral Cancer; Recurrent Bladder Cancer; Recurrent Urethral Cancer; Regional Transitional Cell Cancer of the Renal Pelvis and Ureter; Stage III Bladder Cancer; Transitional Cell Carcinoma of the Bladder; Ureter Cancer; Urethral Cancer Associated With Invasive Bladder CancerLast Updated:January 29, 2014Withdrawn
Condition(s):Urothelial CarcinomaLast Updated:May 25, 2017Terminated
Condition(s):Urothelial CarcinomaLast Updated:March 15, 2018Terminated
Condition(s):Urothelial Carcinoma; Bladder Cancer; Renal Pelvis Cancer; Ureter Cancer; Urethra CancerLast Updated:October 8, 2019Completed
Condition(s):Locally Advanced or Metastatic Urothelial CarcinomaLast Updated:March 21, 2024Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.